PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

Majority of patients continue to be followed for survival with multiple patients approaching 3 years

Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up

Read more at globenewswire.com